Physician profile
William Grace
NPI 1578565610
$6,583.36
in general payments reported to CMS, 2019-2025
50 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,263 · 2020: $1,287 · 2021: $1,489 · 2022: $190 · 2023: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $200 · Food and Beverage: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $200.00 |
| Food and Beverage | $155.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $781.62 | 2019-2023 | |
| Janssen Biotech, INC. | $483.75 | 2019-2022 | |
| Amgen INC. | $389.29 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $377.75 | 2019-2022 | |
| Genzyme Corporation | $370.30 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $347.33 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $293.62 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $246.35 | 2019-2021 | |
| Lilly USA, LLC | $238.85 | 2019-2021 | |
| Puma Biotechnology, INC. | $212.89 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $198.67 | 2019-2021 | |
| Seagen INC. | $192.61 | 2019-2021 | |
| Celgene Corporation | $191.01 | 2019-2022 | |
| Eisai INC. | $190.68 | 2019-2021 | |
| Taiho Oncology, INC. | $182.85 | 2019-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Grace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.